Vivek Sudhakar

Vivek Sudhakar

Auto-generated profile, based on publicly available information

Vivek Sudhakar

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LSLluís Samaranch
Lluís Samaranch
APAzucena Pérez-Cañamás
Azucena Pérez-Cañamás
BSBeatriz Soto-Huelin
Beatriz Soto-Huelin
VSVivek Sudhakar
Vivek Sudhakar
JJJerónimo Jurado-Arjona
Jerónimo Jurado-Arjona
MLMaria Dolores Ledesma
Maria Dolores Ledesma
Gene therapy for Niemann-Pick type A disease is safe in nonhuman primates and has therapeutic effects in a mouse model.

7 September 2022 in Neurosurgery
Verified
Journal Article
Open access
ALAnthony T. Lee
Anthony T. Lee
KHKasey J. Han
Kasey J. Han
NNNoah Nichols
Noah Nichols
VSVivek R. Sudhakar
Vivek R. Sudhakar
JBJohn F. Burke
John F. Burke
DWDoris D. Wang
Doris D. Wang
BACKGROUND: Interventional MRI (iMRI)-guided implantation of deep brain stimulator (DBS) leads has been developed to treat patients with Parkinson's disease (PD) without the need for awake testing. OBJECTIVE: Direct comparisons of targeting accuracy and clinical outcomes for awake stereotactic with asleep iMRI-DBS for PD are limited. METHODS: We performed a retrospective review of patients with PD who underwent awake or iMRI-guided DBS surgery targeting the subthalamic nucleus or globus pallidus interna between 2013 and 2019 at our institution. Outcome measures included Unified Parkinson's Disease Rating Scale Part III scores, levodopa equivalent daily dose, radial error between intended and actual lead locations, stimulation parameters, and complications. RESULTS: Of the 218 patients included in the study, the iMRI cohort had smaller radial errors (iMRI: 1.27 ± 0.72 mm, awake: 1.59 ± 0.96 mm, P < .01) and fewer lead passes (iMRI: 1.0 ± 0.16, awake: 1.2 ± 0.41, P < .01). Changes in Unified Parkinson's Disease Rating Scale were similar between modalities, but awake cases had a greater reduction in levodopa equivalent daily dose than iMRI cases (P < .01), which was attributed to the greater number of awake subthalamic nucleus cases on multivariate analysis. Effective clinical contacts used for stimulation, side effect thresholds, and complication rates were similar between modalities. CONCLUSION: Although iMRI-DBS may result in more accurate lead placement for intended target compared with awake-DBS, clinical outcomes were similar between surgical approaches. Ultimately, patient preference and surgeon experience with a given DBS technique should be the main factors when determining the “best” method for DBS implantation.

30 December 2021 in Acta Neurochirurgica
Verified
Journal Article
Open access
PDF file
RMRamin A. Morshed
Ramin A. Morshed
JYJacob Young
Jacob Young
AGAndrew J. Gogos
Andrew J. Gogos
AHAlexander Fadi Haddad
Alexander Fadi Haddad
JMJames T. McMahon
James T. McMahon
MBMitchel Berger
Mitchel Berger
Background: There is a concern that glioma patients undergoing repeat craniotomies are more prone to complications. The study’s goal was to assess if the complication profiles for initial and repeat craniotomies were similar, to determine predictors of complications, and to compare results with those in the literature. Methods: A retrospective study was conducted of glioma patients (WHO grade II–IV) who underwent either an initial or repeat craniotomy performed by the senior author from 2012 until 2019. Complications were recorded by discharge, 30 days, and 90 days postoperatively. New neurologic deficits were recorded by 90 days postoperatively. Multivariate regression was performed to identify factors associated with complications. A meta-analysis was performed to identify rates of complications based on number of prior craniotomies. Results: Within the cohort of 714 patients, 400 (56%) had no prior craniotomies, 218 (30.5%) had undergone 1 prior craniotomy, and 96 (13.5%) had undergone ≥ 2 prior craniotomies. There were 27 surgical and 10 medical complications in 30 patients (4.2%) and 19 reoperations for complications in 19 patients (2.7%) with no deaths by 90 days. Complications, reoperation rates, and new neurologic deficits did not differ based on number of prior craniotomies. On multivariate analysis, older age (OR1.5, 95%CI 1.0–2.2) and significant leukocytosis due to steroid use (OR12.6, 95%CI 2.5–62.9) were predictors of complications. Complication rates in the cohort were lower than rates reported in the literature. Conclusion: Contrary to prior reports in the literature, repeat craniotomies can be as safe as initial operations if surgeons implement best practices.

1 February 2022 in World Neurosurgery
Verified
Journal Article
Closed access
DCDaniel D. Cummins
Daniel D. Cummins
RMRamin A. Morshed
Ramin A. Morshed
MCMiguel M. Chavez
Miguel M. Chavez
LALauro N. Avalos
Lauro N. Avalos
VSVivek Sudhakar
Vivek Sudhakar
MAManish K. Aghi
Manish K. Aghi

12 January 2018
Verified
Book Chapter
Closed access
PDF file
VSVivek Sudhakar
Vivek Sudhakar
RRR. Mark Richardson
R. Mark Richardson
Gene therapy is a clinical tool that may eventually provide therapeutic benefit to patients suffering from movement disorders through a few potential mechanisms: direct correction of the pathogenic me

31 May 2021 in British Journal Of Neurosurgery
Verified
Journal Article
Closed access
VSVivek Sudhakar
Vivek Sudhakar
RSRaymond F. Sekula
Raymond F. Sekula
Individuals with osteogenesis imperfecta develop pathologic bone due to genetic defects in collagen synthesis. These patients are prone to skull base abnormalities with resultant lower cranial nerve deficits, most common of which is trigeminal neuralgia. Typically, such patients are managed medically, and surgical options are not well explored for those patients, who become refractory to medication management. While microvascular decompression is often recommended for patients with classical trigeminal neuralgia, neurovascular compression by MRI, and normal skull base anatomy, ablative procedures have been described for patients with trigeminal neuralgia and osteogenesis imperfecta. MVD via a retrosigmoid approach has not been described in a patient with trigeminal neuralgia and skull base abnormalities secondary to osteogenesis imperfecta. A 23-year-old man with osteogenesis imperfecta was referred with right-sided classical trigeminal neuralgia. His trigeminal pain had become refractory to a number of medications. High-resolution MRI demonstrated compression of the trigeminal nerve by the superior cerebellar artery. Microvascular decompression of the trigeminal nerve via a retrosigmoid craniectomy was performed, and he remains pain-free 6 months after surgery. Microvascular decompression of the trigeminal nerve through a retrosigmoid approach can be an effective surgical treatment for young patients with trigeminal neuralgia secondary to osteogenesis imperfecta.